Literature DB >> 24126747

Registered nurse assessment and treatment of skin sepsis in New Zealand schools: the development of protocols.

Alison M Vogel1, Diana R Lennon, Sarah Gray, Elizabeth Farrell, Philippa Anderson.   

Abstract

BACKGROUND: Skin infection is the commonest medical cause of hospitalisation in school children. Disadvantaged children, usually Maori or Pacific, have high rates of preventable diseases. AIM: To improve access to early treatment for skin infections using nurse-led school clinics in South Auckland, including provision of antibiotics under delegated standing orders.
METHOD: Evidence-based protocols for the recognition and treatment of skin sepsis were developed following a literature search. A training package was developed for health professionals involved and outcome data were collected from a pilot study in which the protocols were trialled.
RESULTS: An algorithm for diagnosis of skin infections was adapted from Steer et al (Bull World Health Organ. 2009;87:173-9). Fusidic acid ointment was recommended as first-line treatment for localised impetigo. Twice daily oral cephalexin was recommended for extensive impetigo and cellulitis, for palatability and simplicity of dosing. Fifty-six episodes of skin infection received treatment under standing orders in the first 15 weeks of the pilot study.
CONCLUSION: Robust evidence to determine optimal choice, dosage and duration of antibiotic therapy for skin sepsis in children is lacking. The algorithms described are consistent with available evidence and provide a pragmatic approach for use in registered nurse (RN)-led school clinics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24126747

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  1 in total

1.  The rise and fall of hospitalizations for skin infections in New Zealand, 2004-2014: trends by ethnicity and socioeconomic deprivation.

Authors:  A Lim; J Rumball-Smith; R Jones; I Kawachi
Journal:  Epidemiol Infect       Date:  2016-12-01       Impact factor: 4.434

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.